U.S. Markets close in 4 hrs 37 mins

MERGER INVESTIGATION: Kaskela Law LLC Announces Investigation of ConvergeOne Holdings, Inc. - CVON

RADNOR, Pa., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating potential legal claims against the board of directors of ConvergeOne Holdings, Inc. (“ConvergeOne” or the “Company”) (CVON) related to the Company’s entry into an agreement to be acquired by affiliates of CVC Fund VII (“CVC”) in a transaction announced on November 6, 2018 (the “Proposed Transaction”).

On November 6, 2018, the Board caused ConvergeOne to enter into an agreement and plan of merger (the “Merger Agreement”) with CVC.  Pursuant to the terms of the Merger Agreement, shareholders of ConvergeOne will receive $12.50 in cash for each share of ConvergeOne common stock.

On November 21, 2018, ConvergeOne filed a Solicitation/Recommendation Statement with the United States Securities and Exchange Commission (“SEC”) in connection with the Proposed Transaction.  Kaskela Law LLC is investigating possible violations of law related to the Solicitation/Recommendation Statement, including whether the Solicitation/Recommendation Statement omits material information with respect to the Proposed Transaction.

If you own common stock of ConvergeOne and purchased any shares before November 6, 2018, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Kaskela Law LLC (D. Seamus Kaskela, Esquire) at (88) 715 – 1740, via email at skaskela@kaskelalaw.com, or online at http://kaskelalaw.com/case/convergeone-holdings-inc/.

Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and other stockholder actions.  For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.  This notice may constitute attorney advertising in certain jurisdictions.


D. Seamus Kaskela, Esq.
201 King of Prussia Road
Suite 650
Radnor, PA 19087
(484) 258 – 1585
(888) 715 – 1740